AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

conference call. My name is Cameron and I'll facilitate the audio portion of today's interactive broadcast. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star followed by one on your telephone keypad. And if you are having any issues during the call, please press star followed by zero on your telephone keypad. At this time, I would like to turn the call over to Trent Steinmark, Abcelera's Chief Legal and Compliance Officer. You may proceed. Thank you. Hello, everyone. Thank you for joining us for Abcelera's third quarter 2025 earnings call. I'm Trent Steimart, Abcelera's chief legal and compliance officer. Dr. Carl Hansen, Abcelera's president and CEO, and Andrew Booth, Abcelera's chief financial officer, are also on today's call. During this call, we anticipate making projections and forward-looking statements based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially due to several factors outlined in our latest Form 10-K and subsequent Forms 10-Q and 8-Q filed with the Securities and Exchange Commission. EBCLR is not obligated to update any forward-looking statements, whether due to new information, future events, or otherwise. Our presentation today, our earnings press release, and our SEC filings are available on our investor relations website. The information we provide about our pipeline is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that all dollars referred to during the call are U.S. dollars. After our prepared remarks, we will open the...